- Research article
- 2 Fluoroquinolone-resistant Escherichia coli carriage in transrectal prostate biopsy
- 3 patients without infectious complications
- 4 Sofia Kalinen^{a†}, Heini Kallio^{a†}, Juha Knaapila^b, Teemu Kallonen^{c,a}, Eveliina Munukka^{a,c},
- 5 Tarja Lamminen^b, Pentti Huovinen^{a,b}, Peter J. Boström^b, Antti J. Hakanen^{c,a} and Marianne
- 6 Gunell^{c,a}*

- ^aMedical Microbiology and Immunology, Institute of Biomedicine, University of Turku,
- 8 Turku, Finland;
- ^bDepartment of Urology, Turku University Hospital, Turku, Finland;
- ^cDepartment of Clinical Microbiology, Laboratory Division, Turku University Hospital,
- 11 Turku, Finland.

12

16

- *Corresponding author. Clinical microbiology, Turku University Hospital, Kiinamyllynkatu
- 14 10, 20520 Turku, Finland, tel: +358-46-922 1871, email: marianne.gunell@tyks.fi
- †These authors contributed equally to this article.
- 17 Running title: FQ-resistant *E. coli* in TRUS-Bx patients
- 18 Keywords: Ciprofloxacin-resistant, *E. coli*, TRUS-Bx, prophylaxis, resistance mechanisms

Abstract

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Fluoroquinolones are a commonly used prophylaxis in transrectal ultrasound-guided prostate biopsy (TRUS-Bx), even though fluoroquinolone-resistant Escherichia coli has been associated with infectious complications after TRUS-Bx. The present study describes fluoroguinolone resistance mechanisms and antimicrobial susceptibility among intestinal E. coli, isolated from TRUS-Bx patients in a prospective study showing very few infectious prostate biopsy adverse events. This Multi-IMPROD sub-study included a total of 336 patients who received either ciprofloxacin, levofloxacin, or fosfomycin as prophylaxis before TRUS-Bx. E. coli could be cultured from 278 fecal swab samples, and 27 (9.7%) of these showed resistance to ciprofloxacin, and 14 (5.0%) were susceptible with increased exposure (I). Chromosomal and transferable fluoroquinolone resistance mechanisms were found among ciprofloxacin non-susceptible isolates, but both *qnr* genes and single *gyrA* mutations were found also among the ciprofloxacin-susceptible E. coli population. Lowlevel fluoroguinolone resistance is commonly associated with ESBL production in Enterobacterales. However, ESBL and qnr genes were not associated in our material, 14 isolates were ESBL producers and only 14.3% of them had the gnr gene, although 85.7% of the ESBL producers were ciprofloxacin non-susceptible. In the Multi-IMPROD substudy, only two mild urinary tract infections were reported, indicating that the antimicrobial susceptibility or resistance pattern of E. coli does not correlate with the onset of postbiopsy adverse events. We conclude that in our clinical settings, ciprofloxacin and levofloxacin prophylaxis is effective, and no severe post-biopsy infections were detected despite the intestinal colonization of genotypically and phenotypically fluoroquinoloneresistant E. coli.

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Prostate cancer is one of the most common cancer types in men, especially in Western countries. A prostate cancer diagnosis is based on transrectal ultrasound-guided prostate biopsy (TRUS-Bx) which is an invasive procedure, and antimicrobial prophylaxis is a common practice to lower the risk for infectious adverse events. Fluoroquinolones are widely used prophylaxis in prostate biopsy procedures, due to their good penetration to prostate tissue (1). Fluoroquinolone resistance has emerged globally during the last decades, and both fluoroquinolone-resistant Escherichia coli and isolates with reduced susceptibility have increasingly reported to cause sepsis or other infectious adverse events after prostate biopsy procedure (2-6). In Finland, fluoroquinolones are very common per oral treatment for urinary tract infections in men. Fluoroquinolone resistance in both urine and blood E. coli isolates has increased during the last decade, being 15.1% and 10.8%, respectively in Finres data of 2020 (7). The percentage of ESBL-producing E. coli has also increased during the last decade being 6.5% in men's urine isolates and 6.6% in blood isolates in 2020 (7). In Enterobacterales, low-level fluoroquinolone resistance has been associated with ESBL production (8-11), and in Finland, 2.3% of the urine E. coli isolates were both ESBL producers and fluoroquinolone-resistant in 2020 (7). Low-level fluoroquinolone resistance is mainly caused by plasmid-mediated quinolone resistance (PMQR) determinants like *qnr* genes whereas high-level resistance is caused by several chromosomal mutations in the quinolone resistance determining region (QRDR) of DNA gyrase (gyrA/gyrB) and topoisomerase IV genes (parC/parE) (12-14). In E. coli, resistance to fluoroguinolones is highly associated with mutations in gyrA (12). In the present study, we determined the correlation between prostate biopsy adverse events, fluoroquinolone resistance mechanisms and antimicrobial susceptibility among intestinal E. coli isolated from fecal swab samples from men undergoing TRUS-Bx procedure in Finland.

Methods

69

70 Study population. This study is a substudy of IMPROD (Improved Prostate Cancer 71 Diagnosis – Combination of Magnetic Resonance Imaging (MRI) and Biomarkers, NCT02241122) multi-center study (15). A prostate cancer screen with TRUS-Bx was 72 73 performed for patients included in this study and a rectal swab sample was taken during the biopsy procedure. Between March 2015 and May 2017, a total of 336 rectal swab 74 75 samples were collected from four hospitals in Finland: Helsinki University Hospital, 58 samples; Tampere University Hospital, 59 samples; Satakunta Central Hospital, 87 76 77 samples; and Turku University Hospital, 132 samples. Levofloxacin was used as 78 antimicrobial prophylaxis in Turku, and ciprofloxacin in all the other study sites. In Helsinki, 79 patients who had traveled abroad within three months before the TRUS-Bx received fosfomycin instead of ciprofloxacin. 80 81 Bacterial cultures. Swab samples were cultured on ChromAgar Orientation plate (Becton 82 Dickinson, Heidelberg, Germany) and 5 µg-ciprofloxacin disk (OXOID, Thermo Scientific, Helsinki, Finland) was placed on top of the culture to select the patient's most resistant E. 83 coli strain. After the overnight incubation at 35 °C, two to three bacterial colonies with E. 84 85 coli morphology (mauve to light purple colonies) were selected preferably near to the ciprofloxacin disk and pure cultures were made from these on CLED plates (Becton 86 87 Dickinson, Heidelberg, Germany). Maldi-TOF (Bruker, Berlin, Germany) was used for species identification of the isolated strains. Only *E. coli* isolates were studied further. 88 89 Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was performed with 90 the disk diffusion method, according to EUCAST guidelines (16). Following antimicrobial 91 disks were used: ciprofloxacin 5 µg, levofloxacin 5 µg, cefotaxime 5 µg, ceftazidime 10 µg, cefoxitin 30 μg, meropenem 10 μg, ampicillin 10 μg, amoxicillin-clavulanic acid 10/20 μg, 92 mecillinam 10 µg, nitrofurantoin 300 µg, trimethoprim 5 µg, and trimethoprim-93

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

sulfamethoxazole 25 µg (OXOID, Thermo Scientific, Helsinki, Finland). Antimicrobial susceptibility profiles of each E. coli isolates were determined according to EUCAST clinical breakpoint table version 11.0 2021 (17). E. coli ATCC 25922 was used as a control strain in antimicrobial susceptibility testing. PCR amplification and sequencing of chromosomal gyrA and parC gene mutations. Fluoroquinolone resistance mechanisms were studied in all *E. coli* isolates with a ciprofloxacin (CIP) disk inhibition zone ≤30mm. PCR amplification of gyrA and parC genes were performed with primers described in Table 1. The qyrA/parC PCR reaction (50 µL) consisted of 0.2 pmol/µL of each primer, 0.03 U/µL AmpliTag Gold DNA polymerase, 5 µL AmpliTaq Gold buffer, 2 mM MgCl₂ (Thermo Fisher Scientific Oy, Vantaa, Finland), and 0.2 mM dNTP mix (Life Technologies Europe, Espoo, Finland). The PCR program consisted of an initial denaturation at 94°C for 10 minutes, then 37 cycles of DNA denaturation at 94°C for 30 seconds, primer annealing at 55°C for 30 seconds, and extension at 72°C for 90 seconds. PCR-products were purified enzymatically with Exonuclease I- and FastAp Thermosensitive alkaline phosphatase -enzymes (Thermo Fisher Scientific Oy, Vantaa, Finland), and sequenced with BigDye v.3.1 sequencing using ABI3730xl DNA Analyzer at Institute for Molecular Medicine (FIMM, Helsinki, Finland). Detection of plasmid-mediated quinolone resistance genes. Transferable plasmidmediated guinolone resistance (PMQR) gnr genes were screened for all the E. coli isolates with a ciprofloxacin disk inhibition zone ≤30mm. In addition, 34/90 randomly selected isolates with a ciprofloxacin inhibition zone >30mm were studied with previously reported primers and protocols (18). Detection of ESBL genes. Possible ESBL producers were screened according to EUCAST guidelines on the detection of Resistance mechanisms (19). ESBL + AmpC confirmation Kit (Rosco Diagnostics) was used to confirm ESBL production from E. coli isolates with

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

reduced cefotaxime and ceftazidime susceptibility, inhibition zone <21 and <22mm, respectively. ESBL genes (blactx.m blashy and blatem) were screened from these same isolates using previously described primers and PCR protocols (20). Results Antimicrobial susceptibility profiles. E. coli could be isolated from 278 patient samples (out of 336 fecal samples). The highest resistance rates were detected against ampicillin and amoxicillin-clavulanate (27.7% and 24.1%, respectively), also trimethoprim resistance was quite common (14.0%) (Figure 1). Totally 27 (9.7%) E. coli strains were ciprofloxacinresistant i.e. disk inhibition zone was <22mm and 14 (5.0 %) strains were ciprofloxacinsusceptible with increased exposure (I, CIP inhibition zone 22-24mm), according to the 2021 EUCAST breakpoints (17). Furthermore 22 (7.9%) E. coli strains were levofloxacinresistant (R) (Figure 1). With correlation to given prophylaxis, 11 (9.6%) isolates from the levofloxacin group were resistant to both ciprofloxacin and levofloxacin, and six (5.3%) and four (3.5%) were ciprofloxacin- and levofloxacin-susceptible with increased exposure (I), respectively. Among the ciprofloxacin group, 16 (9.8%) and 11 (6.7%) isolates were ciprofloxacin and levofloxacin R, respectively, and eight (4.9%) and 11 (6.7%) isolates were ciprofloxacin and levofloxacin I, respectively. Resistance against cefotaxime and ceftazidime was detected in 14 (5.0%) and 13 (4.7%) E. coli isolates. Of the ciprofloxacin-resistant E. coli isolates, nine (3.2%) were cefotaximeresistant, and eleven (4.0%) showed co-resistance to trimethoprim. These eleven strains were also resistant to ampicillin and sulfamethoxazole-trimethoprim. Four of these were also gentamicin-resistant and three of these were ESBL producing strains. Ten ciprofloxacin-resistant E. coli (3.6%) were also ESBL producers and five (1.8%) isolates were both trimethoprim-resistant and ESBL producers. Antimicrobial susceptibility results from all tested antimicrobials are presented in Figure 1.

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

Fluoroquinolone resistance mechanisms and ESBL producers. Fluoroquinolone resistance mechanisms were found in all fluoroquinolone-non-susceptible isolates, i.e. CIP disk inhibition zone <25mm (17). Of the ciprofloxacin-resistant isolates, 23 had point mutations in the QRDR of both gyrA and parC, and four had point mutations only in gyrA. The most common gyrA mutation was S83L + D87N -double mutation found in 20 isolates, nine of these had also S80I + E84G –double mutation, and ten had S80I –single mutation in parC (Figure 2). Of the 14 *E. coli* isolates being ciprofloxacin I (susceptible with increased dose, according to EUCAST (17), disk inhibition zone 22-24mm), ten had S83L -single mutation and one had D87Y –single mutation in the QRDR of gyrA, and three isolates had only gnr gene (qnrA/B) as their only fluoroquinolone-resistance mechanism detected. Fluoroquinolone resistance mechanisms were also found among ciprofloxacin-susceptible isolates. A total of seven isolates with ciprofloxacin inhibition zone between 25-29mm had a single gyrA mutation, and 31 isolates had gnr gene. The distribution of fluoroquinolone resistance mechanisms among the tested *E. coli* population is presented in Figure 2. According to EUCAST Detection of resistance mechanisms guideline (19), 15 E. coli isolates (5.4%) were ESBL producers, nine of these were positive for bla_{CTX-M} gene, four for bla_{CTX-M}+bla_{TEM}, and one strain for bla_{SHV} +bla_{TEM}. One screening positive isolate did not have any of these three ESBL genes analyzed. Of the ESBL *E. coli* strains, ten were ciprofloxacin-resistant and had chromosomal mutations, two were ciprofloxacin susceptible with increased dose, one of them had qnrS gene and the other had a single gyrA mutation. Two of the ESBL strains were ciprofloxacin-susceptible, but one of these had a single gyrA mutation. The distribution of ESBL genes and fluoroguinolone resistance mechanisms is presented in Figure 2. Fluoroquinolone susceptibility and resistance mechanisms in correlation to post-biopsy adverse events

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

In the Multi-IMPROD study, only 12 minor post-biopsy adverse events were reported.²¹ The list of complications, prophylaxis, and microbiological findings, including ciprofloxacin susceptibility and possible resistance mechanisms of these 12 patients' are presented in Table 2. Discussion In the present study, the antimicrobial susceptibility and fluoroguinolone resistance mechanisms of intestinal *E. coli*, isolated from faecal swab samples from men undergoing prostate biopsy procedures were analysed. Post-biopsy infections are a common side effect of prostate biopsy procedures, and especially fluoroquinolone-resistant and multidrug-resistant E. coli has been reported of being the main factor for infectious adverse events (2-5, 22). Our results showed that 14.7% of the tested E. coli strains were ciprofloxacin non-susceptible, and 85.3% were susceptible according to EUCAST breakpoints (17). If CLSI breakpoints would have been used the number of ciprofloxacinresistant strains would have been the same (CIP ≤21mm), whereas the ciprofloxacin I isolates would have increased from 14 to 19 isolates (CIP 22-25mm vs. CIP 22-24mm) (23). Resistance to levofloxacin was more common in the study population who got levofloxacin prophylaxis than in ciprofloxacin prophylaxis group (9.6% vs. 6.7%, respectively), whereas ciprofloxacin resistance was practically equal in both groups (9.6% vs. 9.8%, respectively). Of the ciprofloxacin-resistant *E. coli*, 4.0% showed co-resistance to trimethoprim, 3.6% of were ciprofloxacin-resistant and ESBL producers, and 1.8% were ciprofloxacin- and trimethoprim-resistant and ESBL producers. Compared to overall susceptibility levels of E. coli isolates in Finland in 2020, fluoroguinolone resistance among the study population was higher compared to invasive isolates (10.8%), but equal to resistance levels in urine isolates (15.1%) (7). ESBL percentage among the intestinal E.

coli isolates was somewhat higher, 5.4%, compared to the earlier reported ESBL carriage

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

rate (4.7%) in Finland (24), but lower compared to ESBL-positivity rate in urine E. coli – isolates (6.5%) (7). In addition, resistance to trimethoprim was lower, whereas multidrug resistance was more common compared to that reported in Finres 2020 (7). To become a high-level fluoroquinolone-resistant, bacterial strain needs to have mutations in both QRDR of qyrA and parC, however mutation even in one of these gene targets. S83L in gyrA, S80I in parC, and D87N in gyrA can cause a clinically relevant fluoroquinolone resistance in *E. coli* (25). In our study, double *gyrA+parC* mutations were detected only in high-level resistant isolates whereas single qyrA mutations were detected even phenotypically ciprofloxacin-susceptible isolates. EUCAST has started using the term ATU (Area of Technical Uncertainty) to warn laboratories that, there can be interpretative difficulties with susceptibility test results in this area, and susceptibility interpretation should be carefully evaluated (26). According to EUCAST breakpoints for ciprofloxacin (17), the ATU area is situated between the resistant and susceptible populations (22-24mm), i.e. I area, and includes the isolates which can be considered susceptible with increased exposure. As we show in Figure 2, isolates within the area of technical uncertainty, have chromosomal gyrase mutations, indicating that it is justified to consider these isolates rather resistant than susceptible. PMQR determinants like qnr genes are linked to low-level fluoroguinolone resistance but these genes also enhance the selection of high-level resistance, furthermore, the *qnr* genes are also easily missed until further mechanisms are acquired and detected (11-12,14, 27-28). We show that the *qnr* genes were detected among ciprofloxacin-resistant, ciprofloxacin I, and ciprofloxacin-susceptible strains, indicating that *gnr* genes do not necessarily have a clinical relevance without additional resistance mechanisms (25). PMQR genes are associated with the same plasmids as ESBL genes (9-11, 27) and there are reports on post-biopsy infections linked to ESBL E. coli isolates with co-resistance to fluoroquinolones (29). In our study, 85.7% of

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

the ESBL strains had chromosomal mutations in QRDR and only one ESBL strain had a PMQR gene as the only fluoroquinolone resistance mechanism, indicating that ESBLproducing strains and strains with qnr genes were not associated in our material. In addition, among the tested ciprofloxacin-susceptible E. coli isolates with disk inhibition zone 31-36mm, no fluoroquinolone resistance determinants were detected, as expected. Despite the ciprofloxacin and multidrug resistance detected in our study population, no severe post-biopsy infections were reported in the Multi-IMPROD study (21). It is known, that the use of fluoroguinolones increases the risk for intestinal colonization of fluoroquinolone-resistant E. coli, and further post-biopsy infectious complications (6,30). In the present study, there were both phenotypically ciprofloxacin-resistant E. coli and isolates with susceptible phenotype but having fluoroquinolone resistance mechanisms, and despite this, only two mild UTI cases were reported. One of them had ciprofloxacinsusceptible E. coli in a swab sample, and the other had ciprofloxacin I E. coli with a single gyrA mutation, indicating that fluoroguinolone resistance alone does not explain the possible adverse events after TRUS-Bx. There are reports on certain E. coli clones, such as ST131 that have spread widely and have caused severe infections (3), and thus further studies are needed to evaluate the role of virulence factors and other resistance mechanisms such as efflux pumps, in post-biopsy infections. Conclusion: We show in this study that fluoroquinolone resistance mechanisms, both the *qnr* genes and gyrA mutations, were also found among the ciprofloxacin-susceptible E. coli population and that ESBL and transferable *qnr* genes were not associated in our material. We conclude that the onset of post-biopsy adverse events did not correlate with antimicrobial susceptibility, since no severe post-biopsy infections were detected despite

- the intestinal colonization of genotypically and phenotypically fluoroquinolone-resistant E.
- 244 coli.

Acknowledgments

We thank Minna Lamppu for her skillful technical assistance with cultured *E. coli* isolates

Funding

This study was funded by the Sigrid Juselius Foundation (for Peter J. Boström), and

Finnish Governmental Special Funding, The Cancer Foundation Finland, University of

Turku Combined Research Funding, and the Turku University Hospital Foundation (for

Juha Knaapila).

Conflict of Interest

All authors declare no conflict of interest regarding this publication.

Transparency declarations

None to declare

References

- 258 1. Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate 259 biopsy. Cochrane Database Syst Rev 2011;(5):CD006576. doi: 260 10.1002/14651858.CD006576.pub2. PMID: 21563156. 261 2. Young JL, Liss MA, Szabo RJ. Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology 2009;74(2):332-8. doi: 262 263 10.1016/j.urology.2008.12.078. Epub 2009 May 22. PMID: 19464041. 3. Williamson DA, Roberts SA, Paterson DL, Sidjabat H, Silvey A, Masters J, Rice M, 264 265 Freeman JT. Escherichia coli bloodstream infection after transrectal ultrasound-quided 266 prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012;54(10):1406-12. doi: 10.1093/cid/cis194. Epub 267 268 2012 Mar 14. PMID: 22419681. 4. Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, 269 270 Semjonow A, Strolin P, Montesino MF, Berge V, Roobol MJ, and Rannikko A. 271 Complications after prostate biopsies in men on active surveillance and its effects on 272 receiving further biopsies in the Prostate cancer Research International: Active Surveillance 273 (PRIAS) study. BJU Int 2016; 118:366-371. doi: 10.1111/bju.13410 [doi]. 274 5. Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, and Verhaegen J. 275 Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal 276 ultrasound-guided prostate biopsy--should we reassess our practices for antibiotic 277 prophylaxis? Clin Microbiol Infect 2012 18:575-581. doi: 10.1111/j.1469-0691.2011.03638.x 278 [doi]. 279 6. Kalalahti I, Huotari K, Lahdensuo K, Tarkka E, Santti H, Rannikko A, Pätäri-Sampo A.
- Kalalahti I, Huotari K, Lahdensuo K, Tarkka E, Santti H, Rannikko A, Pätäri-Sampo A.
 Rectal *E. coli* above ciprofloxacin ECOFF associate with infectious complications following
 prostate biopsy. *Eur J Clin Microbiol Infect Dis* 2018 Jun;37(6):1055-1060. doi:
 10.1007/s10096-018-3217-7. Epub 2018 Mar 2. PMID: 29500572.

283 7. Räisänen K, Ilmavirta H, Vuento R, Hakanen AJ, Salmenlinna S, Gunell M, Jalava J, 284 Rantakokko-Jalava K, Wuorela M, Hyyryläinen HL, Mentula S, Pätäri-Sampo A, Toropainen 285 M, Seiskari T. Bakteerien mikrobilääkeresistenssi Suomessa: Finres 2020. Työpaperi: 286 2021 029. (In Finnish, Figures also in English). THL Terveyden ja hyvinvoinninlaitos. 287 https://urn.fi/URN:ISBN:978-952-343-758-6 288 8. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. Multiplex PCR for detection of 289 plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial 290 isolates. J Antimicrob Chemother 2007; Volume 60, Issue 2: 394– 291 397, https://doi.org/10.1093/jac/dkm204 292 9. Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y, Hu S, Li L. Plasmid-mediated guinolone resistance 293 determinants *qnr* and *aac(6')-lb-cr* in extended-spectrum β-lactamase-294 producing Escherichia coli and Klebsiella pneumoniae in China. J Antimicrob Chemother 2008; Volume 61, Issue 5: 1003–1006, https://doi.org/10.1093/jac/dkn063 295 296 **10.** Veldman K, Dierikx C, van Essen-Zandbergen A, van Pelt W, Mevius D. Characterization of 297 multidrug-resistant, *qnrB2*-positive and extended-spectrum-β-lactamase-298 producing Salmonella Concord and Salmonella Senftenberg isolates. J Antimicrob 299 Chemother 2010; Volume 65, Issue 5: 872–875, https://doi.org/10.1093/jac/dkg049 300 11. Gunell M, Aulu L, Jalava J, Lukinmaa-Åberg S, Österblad M, Ollgren J, Huovinen P, 301 Siitonen A, Hakanen AJ. Cefotaxime-resistant Salmonella enterica in travelers returning 302 from Thailand to Finland. *Emerg Infect Dis* 2014 Jul;20(7): 1214-7. doi: 303 10.3201/eid2007.131744. PMID: 24960266; PMCID: PMC4073843. 304 **12.** Hooper DC. Mechanisms of fluoroquinolone resistance. *Drug Resist Updat* 1999;2(1):38-305 55. doi: 10.1054/drup.1998.0068. PMID: 11504468. 306 **13.** Gunell M, Webber MA, Kotilainen P, Lilly AJ, Caddick JM, Jalava J, Huovinen P, Siitonen 307 A, Hakanen AJ, Piddock LJ. Mechanisms of resistance in nontyphoidal Salmonella enterica 308 strains exhibiting a nonclassical quinolone resistance phenotype. Antimicrob Agents 309 Chemother 2009;53(9):3832-6. doi: 10.1128/AAC.00121-09. Epub 2009 Jul 13. PMID: 310 19596880; PMCID: PMC2737843.

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

14. Hooper DC, Jacoby GA. Topoisomerase Inhibitors: Fluoroguinolone Mechanisms of Action and Resistance. Cold Spring Harb Perspect Med 2016; Sep 1;6(9):a025320. doi: 10.1101/cshperspect.a025320. PMID: 27449972; PMCID: PMC5008060. **15.** Knaapila J, Kallio H, Hakanen AJ, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Gunell M, Boström PJ. Antibiotic susceptibility of intestinal Escherichia coli in men undergoing transrectal prostate biopsies: a prospective, registered, multicentre study. BJU Int 2018;122(2):203-210. doi: 10.1111/bju.14198. Epub 2018 Apr 6. PMID: 29533507. 16. European Committee on Antimicrobial Susceptibility Testing. 2015. Antimicrobial susceptibility testing. EUCAST disk diffusion method. Manual version 5.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/Man ual v 5.0 EUCAST Disk Test.pdf 17. European Committee on Antimicrobial Susceptibility Testing. 2021. The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters, version 11.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST files/Breakpoint tables/v 11.0 Breakpoint Tables.pdf 18. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC, gnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob Agents Chemother 2006;50(8):2872-4. doi: 10.1128/AAC.01647-05. PMID: 16870791; PMCID: PMC1538681. 19. European Committee on Antimicrobial Susceptibility Testing, 2017. The EUCAST guideline on detection of resistance mechanisms, version 2.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/ EUCAST detection of resistance mechanisms 170711.pdf 20. Nyberg SD, Österblad M, Hakanen AJ, Huovinen P, Jalava J, and The Finnish Study Group For Antimicrobial Resistance. Detection and molecular genetics of extended-spectrum

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

beta-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates from Finland, 2002-2004. Scand J Infect Dis 2007; 39:417-424. doi: 777680054 [pii]. 21. Knaapila J, Gunell M, Syvänen K, Ettala O, Kähkönen E, Lamminen T, Seppänen M, Jambor I, Rannikko A, Riikonen J, Munukka E, Eerola E, Hakanen AJ, and Boström PJ. Prevalence of Complications Leading to a Health Care Contact After Transrectal Prostate Biopsies: A Prospective, Controlled, Multicenter Study Based on a Selected Study Cohort. Eur Urol Focus 2019;5(3):443-448. doi: 10.1016/j.euf.2017.12.001. Epub 2017 Dec 20. PMID: 29275146. 22. Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013;57(2):267-74. doi: 10.1093/cid/cit193. Epub 2013 Mar 26. PMID: 23532481. 23. Clinical and Laboratory Standards Institute. 2020. Performance Standards for Antimicrobial Susceptibility testing: M100-ED30:2020. CLSI, Wayne, PA, USA. **24.** Ny S, Kozlov R, Dumpis U, Edguist P, Gröndahl-Yli-Hannuksela K, Kling AM, Lis DO, Lubbert C, Pomorska-Wesolowska M, Palagin I, Vilde A, Vuopio J, Walter J, Wisell KT and NoDARS ESBL-carrier working group. Large variation in ESBL-producing *Escherichia coli* carriers in six European countries including Russia. Eur J Clin Microbiol Infect Dis 2018; 37:2347-2354. doi: 10.1007/s10096-018-3382-8 [doi]. **25.** Huseby DL, Pietsch F, Brandis G, Garoff L, Tegehall A, Hughes D. Mutation Supply and Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli. Mol Biol Evol 2017;34(5):1029-1039. doi: 10.1093/molbev/msx052. PMID: 28087782; PMCID: PMC5400412. 26. European Committee on Antimicrobial Susceptibility Testing, 2019. Area of Technical Uncertainty (ATU) in antimicrobial susceptibility testing. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST files/Disk test documents/AT U/Area of Technical Uncertainty - guidance 2019.pdf

27. Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem? *Clin Microbiol Infect* 2008;14(4):295-7. doi: 10.1111/j.1469-0691.2007.01930.x. Epub 2008 Jan 7. PMID: 18190576.
28. Gunell M, Hakanen AJ, Jalava J, Huovinen P, Österblad M. Hidden qnrB12 gene in a Finnish faecal microbiota isolate from 1994. *J Antimicrob Chemother* 2009;64(4):861-2. doi: 10.1093/jac/dkp304. Epub 2009 Aug 19. PMID: 19692413.
29. Korkmaz N, Gurbuz Y, Sandikci F, Kul G, Tutuncu EE, Sencan I. The Role of Ciprofloxacin Resistance and Extended-spectrum beta-lactamase (ESBL) Positivity in Infective Complications Following Prostate Biopsy. *Urol J*, 2020;17(2):192-197. doi: 10.22037/uj.v0i0.4755. PMID: 31364100.
30. Taylor S, Margolick J, Abughosh Z, Goldenberg SL, Lange D, Bowie WR, Bell R, Roscoe D, Machan L, Black P. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. *BJU Int* 2013;111(6):946-53. doi: 10.1111/j.1464-410X.2012.11637.x. Epub 2013 Mar 6. PMID: 23464844.

Table 1. Primers used in gyrA and parC PCR and Sanger sequencing

379

380

Primer	Target	Sequence (5'-3')
Ecoli_gyrA_307_f	gyrA	AAGCCGGTACACCGTCGCGTACTT
Ecoli_gyrA_570 r	gyrA	TTTCGCCAGACGGATTTCCG
Ecoli_parC_172_f	parC	GTCTGAACTGGGCCTGAATGC
Ecoli_parC_321_r	parC	AGCGGATAACGGTAAGAGAACGG

- Table 2. Patients with post-biopsy adverse events, used prophylaxis, ciprofloxacin
- susceptibility testing results and resistance mechanisms detected.

Sample ID	Prophylaxis	Adverse	E. coli	CIP disk	Susceptibility	FQ-
		event		inhibition	interpretation	resistance
				zone (mm)		mechanism
TA-009	Ciprofloxacin	mild UTI	yes	24	I	S83L
TU-062	Levofloxacin	hematuria	yes	27	S	D87N
HE-056	Ciprofloxacin	hematuria	yes	28	S	qnrA
PO-071	Ciprofloxacin	urine retention	yes	28	S	-
PO-055	Ciprofloxacin	mild UTI	yes	29	S	-
TU-010	Levofloxacin	hematuria	yes	30	S	-
TU-054	Levofloxacin	hematuria	yes	30	S	-
HE-053	Ciprofloxacin	hematuria	yes	31	S	-
PO-075	Ciprofloxacin	urinary	yes	31	S	-
		retention				
TU-146	Levofloxacin	rectal bleeding	yes	31	S	-

TU-026	Levofloxacin	hematuria	yes	32	S	-
HE-047	Ciprofloxacin	hematuria/ urinary retention	no	nd	nd	nd

Figure 1. Antimicrobial susceptibility profiles of 278 E. coli, isolated from fecal swab

samples taken from men undergoing TRUS-Bx

Figure 2. Fluoroquinolone (FQ) resistance mechanisms and ESBL genes detected among 276 *E. coli* isolates with ciprofloxacin (CIP) disk inhibition zone 6-30 mm. A dashed black line with R represents EUCAST and CLSI breakpoint (16, 23) for CIP-resistant isolates. A dashed line with black S represents the EUCAST breakpoint and a grey dashed line with S represents the CLSI breakpoint for CIP susceptible isolates.

R= resistant; S= susceptible

*Randomly selected 34 isolates with disk inhibition zone 31-36mm were tested for qnr genes



